Introduction
============

Multiple sclerosis (MS) is a chronic, demyelinating disease and onset usually occurs at a young age. People with MS have to deal not only with many debilitating and unpredictable symptoms and with the loss of function and the consequent disability, but also with the unpredictability of the disease and the uncertain prognosis. This imposes a significant emotional burden and has a severe impact on psychosocial functioning.

Previous studies focusing on the psychosocial impact of MS have shown that depression, anxiety and reduced quality of life are prevalent ([@B65]; [@B4]; [@B11]; [@B20]; [@B40]; [@B43]). In particular, depression seems to be more prevalent in MS than in other chronic neurological diseases ([@B65]) and three times more prevalent than in the general population ([@B20]). There are reports that depression affects from 15 to 47% of MS patients ([@B14]; [@B57]), with an estimated lifetime prevalence of 50% in people with MS ([@B50]). The prevalence of comorbid depression in MS seems to worsen over time, although it is high even at the time of MS diagnosis ([@B36]). The reasons for the comorbidity of MS and depression are many and complex. Depression could be considered a reaction to the unpredictability and chronicity of the disease, but it is also possible that MS-related biological processes such as immunological and inflammatory pathways, or psychosocial risk factors like inadequate coping or insufficient social support could predispose MS patients to depression ([@B20]; [@B21]; [@B6]). Depression has a negative impact on the course of MS; as well as increasing the symptom burden and negatively influencing adherence to treatment it has direct pathophysiological effects on immunity ([@B39]; [@B6]). It has also been shown that depression in MS is strongly related to lower quality of life, cognitive dysfunction, elevated suicide risk and fatigue ([@B23]; [@B10]; [@B44]; [@B22]; [@B6]), which is one of the most commonly reported and debilitating symptoms of MS ([@B65]). Nevertheless, affective disorders in MS are still under-recognized and under-treated by clinicians ([@B25]). For these reasons the American Academy of Neurology formulated evidence-based recommendations for screening, diagnosis and treatment of psychiatric disorders in MS ([@B38]), recommending further research on the utility of treatments shown to be effective in other clinical populations.

Psychopharmacological treatments, such as serotonin selective reuptake inhibitors (SSRI), are quite effective as treatments for depression in MS, but they have prominent side effects and the drop-out rate is high ([@B31]). In contrast psychological treatments have been shown to have beneficial effects on both depression and quality of life in patients with MS. In particular, cognitive behavioral therapy (CBT) has been shown to have a moderate effect on depression ([@B62]; [@B22]). Feinstein and colleagues ([@B20]; [@B21]) have noted that publicly funded treatments for depression in MS patients must take account of resource constraints and that it is therefore crucial to identify brief, yet cost-effective interventions that can reduce depressive symptoms and the psychological burden of MS, in order to improve patients' quality of life ([@B21]).

Mindfulness-based interventions (MBIs) are psychological treatments that meet the need for brevity and cost-effectiveness. They have been shown to be effective in patients with several diseases, including chronic pain, cancer and fibromyalgia ([@B29]; [@B17]). MBIs influence emotion regulation, using awareness of the present moment and a non-judgmental, accepting attitude, to disrupting dysfunctional tendencies to avoid or over-engage with one's disturbing physical sensations, emotions and thoughts. MBIs have been shown to have large beneficial effects on depression in patients with depressive disorders and to be effective in preventing relapse ([@B29]; [@B46]; [@B33]). Furthermore, MBIs have been shown to produce a moderate reduction in depressive symptoms associated with medical conditions ([@B29]; [@B17]). These results suggest that MBIs could address processes underlying multiple disorders by changing several emotional and cognitive dimensions ([@B29]; [@B20]). Mindfulness can lead patients to relate to their physical and psychological symptoms in a different way, with a positive effect on coping strategies and adaptation to the disease ([@B20]).

Recent systematic reviews have indicated that MBIs are effective in MS patients ([@B58]; [@B35]; [@B51]). Both a review including only controlled trial ([@B58]) and a review using a less restrictive criterion of effectiveness ([@B35]) concluded that MBIs can improve MS patients' quality of life and mental health, and improve ability to cope with some of the physical symptoms, such as fatigue and pain. [@B54] confirmed that in MS, trait mindfulness is related to lower psychological stress, a more constructive coping profile, increased resilience and higher quality of life. [@B7] and [@B52] corroborated these results, suggesting that mindfulness could improve MS patients' quality of life by reducing emotion dysregulation, especially in patients with more symptoms of depression. Moreover, MBIs were shown to have a low overall attrition rate and no side-effects and patients reported high goal satisfaction ([@B26]; [@B58]). However, systematic reviews have also highlighted that most of the data demonstrating the effectiveness of MBIs were obtained in non-controlled trials or in comparison with standard care and argued that there is a need for more rigorous clinical trials comparing MBI with active control groups ([@B35]; [@B58]).

We therefore conducted a randomized controlled trial comparing a MBI with an active control intervention in MS patients with depressive symptoms. We evaluated the effects of a group-based body-affective mindfulness (BAM) intervention on depressive symptoms in patients with MS at the end of the intervention and 6 months later. We also evaluated the effects of the BAM intervention on quality of life, illness perception, symptoms of anxiety, perceived stress and fatigue. We hypothesized that the BAM intervention would be more effective than the control intervention, a psycho-educational intervention. The final aim of this study was to evaluate the effectiveness of the BAM intervention in treating depression and related symptoms and improving quality of life in caregivers. As the caregivers of patients with MS must deal with the stress and difficulties associated with management of a chronic disabling disease we expected that they would also benefit from the treatment.

Materials and Methods {#s1}
=====================

Design
------

We carried out a randomized controlled clinical trial (RCT). MS patients with depressive symptoms were randomly allocated to the BAM group or the active control group, which received a psycho-educational intervention (PEI). The required sample size was calculated to be 82, based on α = 0.05, power = 0.80 and a medium effect size (0.25) with respect to depressive symptoms. The Medical Ethics Committee of San Luigi Gonzaga University Hospital approved the protocol and the study was registered in the ClinicalTrials.gov registry (NCT02611401). All the participants gave written, informed consent.

Participants and Procedures
---------------------------

Participants were enrolled at the CReSM Unit of the San Luigi University Hospital of Orbassano (Italy), the regional referral center for MS.

Multiple sclerosis patients that presented to the CReSM for a routine visit, a blood test or an infusion therapy were invited to participate and complete the Beck Depression Inventory-II (BDI-II) on a consecutive basis. Patients with a BDI-II score greater than 13 who met the other criteria for participation were included in the study.

As previously described ([@B12]), the inclusion criteria were: (1) definite diagnosis of MS (Mc Donald Criteria) ([@B47]) made or confirmed at the CReSM Unit at least 6 months prior the beginning of the study; (2) age between 18 and 65 years; (3) no evidence of clinical relapse and no worsening of score on the Expanded Disability Status Scale (EDSS) in the last 3 months; (4) an EDSS score lower than 6.5; (5) fluent Italian speaker; (6) legal capacity to consent to the treatment; (7) willingness to abstain from or to suspend all other psychological treatment; (8) suspension of all psychotropic medication at least 1 month before the start of the intervention or maintenance at baseline level throughout the study. The exclusion criteria were: (1) current serious psychological or psychiatric disorder, including severe major depressive disorder, psychotic disorder and bipolar disorder or active substance abuse as assessed by the Mini International Neuropsychiatric Interview-Plus (M.I.N.I.-Plus); (2) severe suicidality, including ideation, plan and intent; (3) presence of overt dementia; (4) corticosteroid treatment during the previous 30 days; (5) other serious medical disorders in addition to MS; (6) current pregnancy.

Of the 627 patients with MS who were pre-screened using the BDI-II, 462 did not satisfy the inclusion criteria and 75 refuse to participate (**Figure [1](#F1){ref-type="fig"}**). The final sample consisted of 90 patients. All patients were asked to invite a relative or caregiver to join their treatment group; 19 relatives agreed to participate in the treatment groups.

![Participants flow diagram.](fpsyg-08-02083-g001){#F1}

Patients and caregivers underwent three psychological assessments by trained clinical psychologists who were blind to group status: at baseline (T0), after the intervention (T1) and 6 months after the end of the intervention (follow-up, T2).

Measures
--------

The three psychological assessments included the administration of the following clinical interview and self-report questionnaires.

### Fatigue Severity Scale (FSS)

This is a nine-item self-administered questionnaire, specifically developed to assess the severity of fatigue in various situations and to differentiate fatigue from clinical depression ([@B32]). Scores greater than 36 suggest the presence of severe fatigue. The FSS has shown high Cronbach's alpha values (0.84--0.95) in patients with MS ([@B49]).

### Beck Depression Inventory-II (BDI-II)

This is a 21-item self-report instrument that assesses the presence and severity of depressive symptoms, based on the DSM-IV criteria ([@B3]). Total score ranges from 0 to 63, with higher scores indicating higher levels of depressive symptoms. The Consensus Group for Depression in MS ([@B25]) and the American Academy of Neurology ([@B38]) consider the BDI-II (with a cut-off score of 13) the best method of screening for depression in MS patients. The internal consistency of the BDI-II is good to excellent (α = 0.83--0.96) ([@B66]).

### Beck Anxiety Inventory (BAI)

This is a 21-item self-report measure with high internal consistency (α = 0.92) that assesses the severity of cognitive, somatic and affective anxiety symptoms ([@B1]; [@B2]). Total score ranges from 0 to 63, with higher scores indicating higher levels of anxiety. Scores higher than 9 suggest the presence of clinical anxiety (10-16: mild anxiety; 17-29: moderate anxiety; ≥30: severe anxiety).

### Perceived Stress Scale (PSS)

This is a 10-item questionnaire measuring the extent to which the respondent perceives his or her life situation as stressful ([@B16]). Higher scores indicate a higher level of stress. The scale has shown an acceptable to excellent internal reliability (α = 0.78--0.91) ([@B15]).

### Brief Illness Perception Questionnaire (B-IPQ)

This is a nine-item self-report questionnaire that assesses emotional and cognitive representations of illness ([@B8]). Higher scores indicate a more negative perception of one's illness. A recent systematic assessment of the reliability of the B-IPQ confirmed that it has good psychometric properties, including concurrent, predictive and discriminant validity ([@B9]).

### Functional Assessment of Multiple Sclerosis (FAMS)

This is a self-report scale designed to assess six aspects of quality of life in patients with MS: Mobility, Symptoms, Emotional Wellbeing, General Contentment, Thinking and Fatigue, and Family/Social Wellbeing ([@B13]). Higher scores indicate better quality of life. The FAMS has good internal consistency, with Cronbach's alpha for the subscales ranging from 0.82 to 0.96 ([@B59]).

### Mini International Neuropsychiatric Interview-Plus (M.I.N.I.-Plus)

This is a brief, structured diagnostic interview for the major Axis I psychiatric disorders compatible with the *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition (DSM-IV) criteria ([@B55]). The M.I.N.I.-Plus has shown good inter-rater reliability and test--retest reliability ([@B55]).

Caregivers were asked to complete the BDI-II and the BAI to provide measures of their depressive and anxiety symptoms respectively. They also completed the PSS and the WHO-Quality of Life-Bref (WHOQOL-Bref; [@B41]). The WHOQOL-Bref consists of 26 questions, two assess overall quality of life and the six relating to each of the following four domains: physical; psychological; social relationships; environment. The WHOQOL-Bref has shown good discriminant validity, test--retest reliability and internal consistency (α = 0.65-0.80) ([@B18]).

Randomization and Blinding
--------------------------

Patients were randomly assigned into the two intervention groups with a 1:1 ratio (45 in the BAI and 45 in the PEI group), using a block-wise randomization sequence (block size of 4 and 6). To ensure allocation concealment, the sequence was determined by an independent researcher blind to the initial assessment, using a random number generator^[1](#fn01){ref-type="fn"}^. To ensure the blinding of the clinical psychologists performing the assessments, the study coordinator communicated the treatment assignment to each patient.

Because family members or caregivers joined the group to which the corresponding patient had been randomly assigned it was not possible to stratify this variable; however we expected that the randomization of patients would ensure that participating caregivers were randomly and evenly distributed across groups.

Intervention
------------

The interventions were led by trained clinical psychologists who were blind to the results of the baseline assessment. Both interventions consisted of an 8-week group program, consisting of weekly 3-h sessions.

### Body-Affective Mindfulness (BAM) Intervention

The MBI used in this study is called body-affective mindfulness (BAM); BAM is based on (1) awareness practices such as body scan, breath meditation, walking meditation and yoga exercises; (2) mindfulness in relationship practices such as loving kindness, enriching listening to nature and persons and self-compassion; (3) sensorimotor psychotherapy ([@B42]). Sensorimotor psychotherapy emphasizes the use of somatic resources to attain and sustain a mindful disposition and integrates the concept of a stress response with the concept of a "window of tolerance" ([@B56]), in order to maximize the clinical utility of the intervention and tailor it to MS patients ([@B30]). A more detailed description of the treatment protocol has been provided elsewhere ([@B12]).

In addition to the eight weekly sessions, the BAM intervention also included an all-day (7-h) session and participants were required to carry out daily 45-min homework assignments, which consisted of mindfulness exercises and applications of mindfulness to everyday life.

### Psycho-Educational Intervention (PEI)

We used a control intervention based on that used by [@B27] to control for the non-specific elements of the BAM treatment. The PEI was based on a psycho-educational framework and involved discussion of MS-related topics. The group practiced relaxation techniques and gentle stretching exercises at the end of each session. Participants were given handouts covering the topics discussed and encouraged to practice the exercises and techniques they had been shown as homework. The PEI was conducted by a psychotherapist with experience in relaxation training and in working with people with MS and followed the same weekly format as the BAM intervention, with the exception of the all-day session.

Statistical Analysis
--------------------

Data were analyzed using the Statistical Package for Social Science -- Version 24 (SPSS-24; IBM SPSS Statistics for Macintosh, Version 24.0. Armonk, NY, United States: IBM Corp.).

Student's *t*-test or the Mann--Whitney *U* test (where the Kolmogorov--Smirnov test indicated that distribution departed from normality) were used to analyze baseline group differences in continuous measures and Fisher's Exact Test was used for categorical measures. The Mann--Whitney *U* test and Fisher's Exact Test were also used for within-group baseline comparisons of the socio-demographic and clinical characteristics of completers and drop-outs.

GLM repeated-measures ANOVAs were conducted to evaluate the effects of group (BAM vs. PEI) and time (T0 vs. T1 vs. T2) and the time by group interaction, including only patients who completed the entire clinical trial according to the protocol \[per-protocol (PP) analyses\]. Mauchly's test was used to assess violations of the sphericity assumption and the Greenhouse-Geisser correction was applied where necessary. Repeated-measures ANOVA is quite robust against violations of the assumptions of normality and sphericity ([@B60]; [@B5]). When the sphericity violation is only slight (𝜀 \> 0.75) applying the Greenhouse-Geisser correction provides a conservative assessment of differences ([@B5]).

Where significant effects were found, pairwise comparison were carried out applying the Bonferroni correction. Results of the *post hoc* comparison were presented as mean difference (MD) with 95% confidence interval (CI) and standard error (SE).

Finally, we performed an exploratory ITT analysis to take into account the missing data. All tests were two-sided and the level of significance was set at *p* \< 0.05.

Results
=======

A flow diagram with the number of participants at each assessment stage is presented in **Figure [1](#F1){ref-type="fig"}**. Ninety patients were randomized: 45 were assigned to the BAM intervention and 45 to the PEI.

Baseline Characteristics
------------------------

There were no group differences in socio-demographic and clinical characteristics at baseline (**Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}**). Patients reported moderate levels of depression and anxiety symptoms and high levels of fatigue and of perceived stress. Our sample also had generally negative illness representations and an unsatisfactory quality of life (**Table [2](#T2){ref-type="table"}**).

###### 

Demographic and clinical characteristics of randomized multiple sclerosis patients in the two intervention groups.

                              BAM (*N* = 45)   PEI (*N* = 45)   Test               *p*
  --------------------------- ---------------- ---------------- ------------------ ----------
  Age                         44.1 (9.4)       45.1 (9.3)       *t*(88) = -0.496   0.621^a^
  Years of education          13 (2)           13 (5)           *U* = 899          0.340^b^
  Time since diagnosis        9 (10)           7 (7)            *U* = 885          0.303^b^
  EDSS                        2 (1)            2.5 (2.3)        *U* = 806          0.127^b^
                                                                                   
                              **N (%)**        **N (%)**                           
                                                                                   
  Sex                                                                              1^c^
  M                           13 (28.9)        13 (28.9)                           
  F                           32 (71.1)        32 (71.1)                           
  Marital status                                                                   0.739^c^
  Single                      15 (33.3)        12 (26.7)                           
  Married                     23 (51.1)        24 (53.3)                           
  Divorced                    7 (15.6)         9 (20)                              
  Employment status                                                                0.503^c^
  Unemployed                  13 (28.9)        17 (37.8)                           
  Employed                    31 (68.9)        28 (62.2)                           
  Student                     1 (2.2)          0 (0)                               
  MS type                                                                          0.663^c^
  Relapsing-remitting         38 (88.4)        36 (8%)                             
  Primary progressive         1 (2.3)          1 (2.2)                             
  Secondary progressive       3 (7)            4 (8.9)                             
  Progressive relapsing       1 (2.3)          4 (8.9)                             
  Pharmacological treatment   36 (80)          36 (80)                             1^c^

a

t

-test;

b

Mann--Whitney

U

test;

c

Fisher Exact test. MS, multiple sclerosis; EDSS, Expanded Disability Status Scale.

###### 

Comparison of clinical outcome measures at baseline between multiple sclerosis patients randomized in the two intervention groups.

                              BAM (*N* = 45)   PEI (*N* = 45)                       
  --------------------------- ---------------- ---------------- ------------------- ----------
  FSS                         50 (17)          51 (23)          *U* = 995           0.888^b^
  Above cut-off               *35 (77.8%)*     *33 (73.3%)*     *X^2^*(1) = 0.241   0.807^c^
  BDI-II                      19 (11)          20 (10)          *U* = 887           0.310^b^
  Above cut-off               *45 (100%)*      *45 (100%)*                          
  BAI                         15 (17)          17 (18)          *U* = 919.5         0.453^b^
  Above cut-off               *32 (71.1%)*     *33 (73.3%)*     *X^2^*(1) = 0.055   1^c^
  PSS                         25 (7)           24 (31)          *U* = 889           0.318^b^
  B-IPQ                       49.42 (8.83)     51.69 (9.72)     *t*(88) = -1.16     0.25^a^
  FAMS                                                                              
  *Total score*               109.6 (25.5)     104.2 (23.5)     *t*(87) = 1.02      0.309^a^
  *Mobility*                  20 (9)           16.5 (7)         *U* = 849           0.246^b^
  *Symptoms*                  19.33 (4.95)     19.81 (5.34)     *t*(87) = -0.434    0.665^a^
  *Emotional wellbeing*       19.83 (7)        18 (6.75)        *U* = 818.5         0.158^b^
  *General contentment*       14.44 (5.79)     13.48 (4.98)     *t*(87) = 0.845     0.401^a^
  *Thinking and fatigue*      21 (10.5)        20.5 (6)         *U* = 914.5         0.535^b^
  *Family/Social wellbeing*   17.73 (4.63)     16.22 (6.16)     *t*(79.8) = 1.3     0.196^a^
  *Additional concerns*       33.95 (7.13)     32.46 (7.54)     *t*(87) = 0.956     0.342^a^

a

t

-test;

b

Mann--Whitney

U

test;

c

Fisher Exact test. Mean (

SD

), Median (IQR), or

N

(%) are shown, accordingly. FSS, Fatigue Severity Scale; BDI-II, Beck Depression Inventory-II; BAI, Beck Anxiety Inventory; PSS, Perceived Stress Scale; B-IPQ, Illness Perception Questionnaire-Brief; FAMS, Functional Assessment of Multiple Sclerosis.

After group allocation 5 of 45 patients (11.1%) assigned to the BAM and 3 of the 45 (6.7%) patients assigned to the PEI group declined to participate (**Figure [1](#F1){ref-type="fig"}**). Of the 82 patients who began the intervention, 4 (10%) (BAM) and 7 (16.7%) (PEI) failed to complete the intervention.

A comparison of completers and drop-outs found no baseline difference in the socio-demographical and clinical characteristics of those assigned to BAM intervention. In the case of the PEI group there were baseline differences between completers and drop-outs with respect to BAI score (*U* = 82.5, *p* = 0.011), PSS score (*U* = 89.5, *p* = 0.019) and Thinking and Fatigue subscale of the FAMS score (*U* = 91.5, *p* = 0.027), with drop-outs having lower anxiety \[Mdn (IQR) = 9 (13) vs. 19.5 (19)\] and lower perceived stress \[Mdn = 14 (13) vs. 25 (10)\] than completers as well as better quality of life in terms of the Thinking and Fatigue subscale \[Mdn (IQR) = 23.5 (8) vs. 19 (5.25)\].

Per-protocol Analyses
---------------------

We compared the impact of the interventions on the clinical outcome variables in completers (BAM: *N* = 36; PEI: *N* = 35) (**Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}**).

###### 

Repeated measures ANOVA on multiple sclerosis patients' clinical outcome measures (per-protocol analyses).

                 T0              T1              T2              F                                 *p*       $\eta_{p}^{2}$
  -------- ----- --------------- --------------- --------------- --------------------------------- --------- ----------------
  FSS      BAM   46.25 (11.55)   40.92 (13.46)   41.61 (13.46)   Time: *F*(2,138) = 2.21           0.113     0.031
           PEI   45.23 (15.46)   45.51 (12.21)   45.69 (14.53)   Group: *F*(1,69) = 0.81           0.373     0.012
                                                                 T × G: *F*(2,138) = 7.93          0.057     0.041
  BDI-II   BAM   21.39 (7.38)    10.28 (9.05)    10.03 (7.42)    Time: *F*(2,138) = 64.43          \<0.001   0.487
           PEI   22.63 (7.36)    17.51 (11.08)   16.11 (11.32)   Group: *F*(1,69) = 6.45           0.013     0.086
                                                                 T × G: *F*(2,138) = 6.79          0.002     0.090
  BAI      BAM   17.06 (11.09)   14.19 (11.84)   16.17 (10.18)   Time: *F*(2,138) = 3.46           0.034     0.048
           PEI   20.8 (11.43)    17.71 (10.94)   18.11 (10.84)   Group: *F*(1,69) = 1.82           0.181     0.026
                                                                 T × G: *F*(2,138) = 0.37          0.692     0.005
  PSS      BAM   23.92 (6.83)    18.33 (7.68)    20.19 (7.3)     Time: *F*(2,138) = 10.79          \<0.001   0.135
           PEI   24.2 (7.28)     22.37 (5.89)    22.94 (6.94)    Group: *F*(1,69) = 2.94           0.091     0.041
                                                                 T × G: *F*(2,138) = 2.75          0.067     0.038
  B-IPQ    BAM   49.81 (9.04)    44.92 (9.48)    44.94 (9.59)    Time: *F*(1.77,122.2) = 7.54      0.001     0.098
           PEI   51.86 (10.34)   50.54 (10.51)   51.54 (10.02)   Group: *F*(1,69) = 5.06           0.028     0.068
                                                                 T × G: *F*(1.77,122.17) = 30.91   0.027     0.054

T × G, time by group interaction effect. FSS, Fatigue Severity Scale; BDI-II, Beck Depression Inventory-II; BAI, Beck Anxiety Inventory; PSS, Perceived Stress Scale; B-IPQ, Illness Perception Questionnaire-Brief.

###### 

Repeated measures ANOVA on multiple sclerosis patients' quality of life assessed with the Functional Assessment of Multiple Sclerosis questionnaire (per-protocol analyses).

                                    T0              T1              T2              F                                *p*     $\eta_{p}^{2}$
  --------------------------- ----- --------------- --------------- --------------- -------------------------------- ------- ----------------
  *Total score*               BAM   110.9 (23.61)   121 (25.76)     120.4 (24.17)   Time: *F*(2,136) = 3.25          0.042   0.046
                              PEI   101.3 (24.42)   101.5 (25.55)   97.35 (25.04)   Group: *F*(1,68) = 10.32         0.002   0.132
                                                                                    T × G: *F*(2,136) = 7.63         0.001   0.101
  *Mobility*                  BAM   18.31 (5.64)    19.19 (5.53)    18.86 (5.67)    Time: *F*(2,136) = 0.55          0.579   0.008
                              PEI   16.28 (5.38)    15.92 (5.26)    15.16 (5.21)    Group: *F*(1,68) = 6.5           0.013   0.087
                                                                                    T × G: *F*(2,136) = 2.12         0.125   0.030
  *Symptoms*                  BAM   19.33 (4.34)    20.33 (4.43)    20.5 (4.13)     Time: *F*(2,136) = 0.19          0.831   0.003
                              PEI   19.57 (5.33)    18.27 (5.21)    18.35 (5.86)    Group: *F*(1,68) = 1.67          0.200   0.024
                                                                                    T × G: *F*(2,136) = 5.5          0.005   0.075
  *Emotional wellbeing*       BAM   19.69 (5.38)    22.31 (5.24)    21.94 (5.69)    Time: *F*(1.76,120.1) = 7.68     0.001   0.101
                              PEI   17.09 (5.41)    18.57 (5.58)    17.71 (5.91)    Group: *F*(1,68) = 9.3           0.003   0.120
                                                                                    T × G:F(1.76,120.1) = 1.44       0.241   0.021
  *General contentment*       BAM   14.86 (6.07)    16.78 (5.75)    17.11 (5.67)    Time: *F*(1.74,118.4) = 3.54     0.038   0.049
                              PEI   13.09 (5.05)    13.63 (5.33)    12.71 (4.77)    Group: *F*(1,68) = 6.88          0.011   0.092
                                                                                    T × G: *F*(1.74,118.38) = 3.93   0.027   0.055
  *Thinking and fatigue*      BAM   20.81 (7.31)    24.03 (7.16)    23.78 (5.81)    Time: *F*(2,136) = 2.60          0.078   0.037
                              PEI   19.33 (6.80)    19.11 (7.91)    18.43 (7.88)    Group: *F*(1,68) = 6.72          0.012   0.090
                                                                                    T × G: *F*(2,136) = 6.51         0.020   0.087
  *Family/social wellbeing*   BAM   17.89 (4.48)    18.39 (5.35)    18.22 (4.51)    Time: *F*(2,136) = 0.87          0.423   0.013
                              PEI   15.97 (6.47)    16.01 (6.11)    15 (6.18)       Group: *F*(1,68) = 4.17          0.050   0.058
                                                                                    T × G: *F*(2,136) = 1.13         0.326   0.016
  *Additional concerns*       BAM   33.91 (7.37)    35.36 (8.53)    34.81 (7.93)    Time: *F*(2,136) = 0.36          0.700   0.005
                              PEI   32.31 (8.16)    31.66 (8.74)    32.6 (8.45)     Group: *F*(1,68) = 2.25          0.138   0.032
                                                                                    T × G: *F*(2,136) = 1.67         0.191   0.024

T × G, time by group interaction effect.

### Depressive Symptoms (**Table [3](#T3){ref-type="table"}**)

There were group and time effects on BDI-II as well as a medium-sized group by time interaction (*p* \< 0.002; $\eta_{p}^{2}$ = 0.09). Compared with baseline, both interventions reduced depressive symptoms at T1 (BAM: MD = 11.11, 95% CI: 8.17 -- 14.57, *SE* = 1.2, *p* \< 0.001; PEI: MD = 5.11, 95% CI: 2.13 -- 8.1, *SE* = 1.2, *p* \< 0.001). In both groups the improvement remained stable at the follow-up (BAM: MD = 0.25, 95% CI: -2.49 -- 2.99, *SE* = 1.12, *p* = 1; PEI: MD = 1.4, 95% CI -1.38 -- 4.18, *SE* = 1.13, *p* = 0.66). However, pairwise comparison revealed that BAM intervention was more effective than the PEI, at T1 (MD = -7.24, 95% CI: -12.02 -- -2.45, *SE* = 2.4, *p* = 0.004) and at T2 (MD = -6.09, 95% CI: -10.61 -- -1.57, *SE* = 2.27, *p* = 0.009).

### Fatigue (**Table [3](#T3){ref-type="table"}**)

There was no effect of time or group on FSS score, indicated that neither intervention improved fatigue symptoms.

### Anxiety Symptoms (**Table [3](#T3){ref-type="table"}**)

There was a medium-sized main effect of time on BAI score. Pairwise comparison confirmed an overall reduction in symptoms between baseline and T1 (MD = 2.97, 95% CI: 0.120 -- 5.83, *SE* = 1.16, *p* = 0.038), which remained stable between T1 and T2 (MD = -1.19, 95% CI: -3.78 -- 1.41, *SE* = 1.06, *p* = 0.796). However, the BAM intervention was no more effective than the PEI, i.e., there was no time by group interaction.

### Perceived Stress Symptoms (**Table [3](#T3){ref-type="table"}**)

There was a medium-sized main effect of time on PSS score, such that both interventions reduced perceived stress at T1 relative to baseline (MD = 3.71, 95% CI: 1.72 -- 5.69, *SE* = 0.81, *p* \< 0.001). The reduction remained stable between T1 and T2 (MD = -1.22, 95% CI: -3.15 -- 0.72, *SE* = 0.79, *p* = 0.380). There was no main effect of group and no time by group interaction.

### Illness Perception (**Table [3](#T3){ref-type="table"}**)

There were medium-sized main effects of time and group on B-IPQ score. There was a time by group interaction, reflecting the lack of change in perception of illness in the PEI group (T0 *vs.* T1: MD = 1.31, 95% CI: -1.71 -- 4.34, *SE* = 1.23, *p* = 0.869; T1 *vs.* T2: MD = -1, 95% CI -3.47 -- 1.47, *SE* = 1, *p* = 0.969). In contrast the BAM intervention improved B-IPQ score at T1 (MD = 4.89, 95% CI: 1.91 -- 7.87, *SE* = 1.21, *p* \< 0.001) and this improvement that remain stable at T2 (MD = -0.03, 95% CI -2.49 -- 2.4, *SE* = 0.99, *p* = 1); in other words patients rated their illness as less threatening after the BAM intervention than at baseline.

### Quality of Life (**Table [4](#T4){ref-type="table"}**)

Repeated-measures ANOVA showed a medium-sized time by group interaction size with respect to the total score of the FAMS. The BAM intervention, but not the PEI, improved patients' quality of life at T1 relative to baseline (MD = -10.14, 95% CI: -16.19 -- -4.09, *SE* = 2.47, *p* \< 0.001) and this improvement remained stable at T2 (MD = 0.62, 95% CI: -5.37 -- 6.61, *SE* = 2.44, *p* = 1).

There were time by group interactions with respect to scores on the Symptoms, General Contentment, and Thinking and Fatigue subscales, these effects ranged from medium to small in size. Pairwise comparisons confirmed that the BAM intervention, but not the PEI, led to improvements at T1 relative to baseline (General Contentment: MD = -1.92, 95% CI: -3.39 -- -0.44, *SE* = 0.6, *p* = 0.006; Thinking and Fatigue: MD = -3.22, 95% CI: -5.48 -- -0.97, *SE* = 0.92, *p* = 0.002), that were maintained at T2 (General Contentment: MD = -0.33, 95% CI: -1.75 -- 1.09, *SE* = 0.58, *p* = 1; Thinking and Fatigue: MD = 0.25, 95% CI: -1.73 -- 2.23, *SE* = 0.81, *p* = 1). In the case of the Symptoms subscale pairwise comparisons revealed no differences.

There was a main effect of group on Mobility subscale score, with higher scores overall in the BAM group than the PEI group (MD = 3.06, 95% CI: -3.39 -- -0.44, *SE* = 1.2, *p* = 0.013). Finally, there were medium-sized main effects of time and group on Emotional Wellbeing subscale scores. Pairwise comparisons showed that overall emotional wellbeing was better in the BAM group than the PEI group (MD = 3.6, 95% CI: 1.24 -- 5.95, *SE* = 1.18, *p* = 0.003). There were also overall increases in scores between baseline and T1 (MD = -1.94, 95% CI: -3.09 -- -0.8, *SE* = 0.47, *p* \< 0.001), suggesting that both groups showed improvements in emotional wellbeing.

### Psychopathology

At baseline the results of the M.I.N.I.-Plus suggested that adjustment disorders (BAM: 47.2%; PEI: 28.6%), anxiety disorders (including generalized anxiety disorders, panic disorders, phobia, etc.) (BAM: 33.3%; PEI: 20%) and major depressive episode (BAM: 30.6%; PEI: 37.1%) were prevalent in both groups. The proportion of participants no longer meeting the criteria for these disorders after the intervention was higher in the BAM group than the PEI group (see Supplementary Table [1](#SM1){ref-type="supplementary-material"}).

ITT Analyses (**Table [5](#T5){ref-type="table"}**)
---------------------------------------------------

###### 

Repeated measures ANOVA on the entire randomized multiple sclerosis patients (ITT analyses).

                                     T0              T1              T2              *F*                             *p*       $\eta_{p}^{2}$
  ---------------------------- ----- --------------- --------------- --------------- ------------------------------- --------- ----------------
  FSS                          BAM   46.62 (10.91)   41.53 (12.79)   42.2 (12.75)    Time: *F*(2,176) = 4.6          0.011     0.050
                               PEI   45.38 (14.93)   44.36 (13.02)   44.84 (14.83)   Group: *F*(1,88) = 0.31         0.577     0.004
                                                                                     T × G: *F*(2,176) = 2.3         0.103     0.026
  BDI-II                       BAM   20.91 (7.41)    11.71 (9.84)    11.47 (9.50)    Time: *F*(1.81,158.9) = 65.6    \<0.001   0.427
                               PEI   21.64 (7.06)    16.22 (10.45)   14.6 (10.79)    Group: *F*(1,88) = 2.6          0.111     0.029
                                                                                     T × G: *F*(1.81,158.9) = 2.94   0.061     0.032
  BAI                          BAM   16.71 (10.93)   14.31 (12.13)   15.31 (10.19)   Time: *F*(2,176) = 2.15         0.119     0.024
                               PEI   18.56 (11.34)   17.16 (10.94)   16.67 (10.27)   Group: *F*(1,88) = 1            0.319     0.011
                                                                                     T × G: *F*(2,176) = 0.29        0.747     0.003
  PSS                          BAM   23.89 (6.8)     18.4 (7.77)     19.71 (7.52)    Time: *F*(2,176) = 11           \<0.001   0.111
                               PEI   22.69 (7.64)    21.4 (6.39)     21.89 (7.03)    Group: *F*(1,88) = 1.12         0.292     0.013
                                                                                     T × G: *F*(2,176) = 4.43        0.013     0.048
  B-IPQ                        BAM   49.42 (8.83)    45.58 (9.45)    44.96 (9.31)    Time: *F*(1.73,152.2) = 8.95    \<0.001   0.092
                               PEI   51.69 (9.72)    49.71 (10.05)   50.82 (9.40)    Group: *F*(1,88) = 5.21         0.025     0.056
                                                                                     T × G: *F*(1.73,152.2) = 2.78   0.073     0.031
  FAMS                                                                                                                         
  *Total score*                BAM   109.6 (25.5)    119.3 (28.30)   119.1 (27.1)    Time: *F*(2,174) = 5.54         0.005     0.060
                               PEI   104.2 (23.50)   105.7 (24.80)   103.3 (26.4)    Group: *F*(1,87) = 5.24         0.025     0.057
                                                                                     T × G: *F*(2,174) = 5.76        0.004     0.062
  *Mobility*                   BAM   17.87 (6.01)    18.67 (5.84)    18.16 (6.09)    Time: *F*(2,174) = 0.52         0.593     0.006
                               PEI   17.01 (5.50)    16.34 (5.26)    16.07 (5.6)     Group: *F*(1,87) = 2.51         0.117     0.028
                                                                                     T × G: *F*(2,174) = 2.59        0.078     0.029
  *Symptoms*                   BAM   19.33 (4.95)    20.29 (5.04)    20.87 (4.62)    Time: *F*(2,174) = 0.33         0.722     0.004
                               PEI   19.81 (5.34)    18.94 (5.31)    18.77 (5.82)    Group: *F*(1,87) = 1.02         0.315     0.012
                                                                                     T × G: *F*(2,174) = 6.71        0.002     0.072
  *Emotional wellbeing*        BAM   19.13 (5.38)    21.65 (5.72)    21.53 (5.88)    Time: *F*(1.75,151.9) = 11.21   \<0.001   0.114
                               PEI   17.36 (5.54)    19.2 (5.43)     18.3 (5.62)     Group: *F*(1,87) = 5.78         0.018     0.062
                                                                                     T × G: *F*(1.75,151.9) = 1.22   0.294     0.014
  *General contentment*        BAM   14.44 (5.79)    16.36 (5.87)    16.62 (5.98)    Time: *F*(1.67,145.4) = 6.02    0.005     0.065
                               PEI   13.48 (4.98)    14.24 (5.34)    13.95 (5.33)    Group: *F*(1,87) = 3.27         0.074     0.036
                                                                                     T × G: *F*(1.67,145.4) = 1.95   0.153     0.022
  *Thinking and fatigue*       BAM   21.07 (7.63)    24.04 (7.93)    23.93 (6.6)     Time: *F*(2,174) = 4.39         0.014     0.048
                               PEI   20.37 (6.77)    20.16 (7.92)    20.33 (8.32)    Group: *F*(1,87) = 3.44         0.067     0.038
                                                                                     T × G: *F*(2,174) = 5.21        0.006     0.057
  *Family/Social Well-Being*   BAM   17.73 (4.63)    18.24 (5.10)    17.96 (4.88)    Time: *F*(2,174) = 0.89         0.413     0.010
                               PEI   16.22 (6.16)    16.54 (5.92)    15.84 (5.98)    Group: *F*(1,87) = 2.77         0.100     0.031
                                                                                     T × G: *F*(2,174) = 0.31        0.737     0.004
  *Additional Concerns*        BAM   33.95 (7.13)    35.04 (8.63)    35.07 (7.94)    Time: *F*(1.87,162.9) = 1.06    0.346     0.012
                               PEI   32.46 (7.54)    32.62 (8.15)    33.21 (7.8)     Group: *F*(1,87) = 1.85         0.178     0.021
                                                                                     T × G: *F*(1.87,162.9) = 0.50   0.597     0.006

T × G, time by group interaction effect; FSS, Fatigue Severity Scale; BDI-II, Beck Depression Inventory-II; BAI, Beck Anxiety Inventory; PSS, Perceived Stress Scale; B-IPQ, Illness Perception Questionnaire-Brief; FAMS, Functional Assessment of Multiple Sclerosis.

An ITT analysis was also performed on the whole randomized sample. Only two patients (they were amongst those who declined to participate in the BAM group) refused to complete the T1 and T2 assessments. In the case of these two patients baseline data were substituted for the missing T1 and T2 data. The results generally confirmed the PP findings on the effectiveness of the BAM, especially with regard to quality of life (FAMS). In the ITT analyses the time by group interaction for BDI-II score was no longer significant (*p* = 0.061), although in descriptive terms it was only the BAM group which had a mean score below the threshold after the intervention. The ITT analyses did show, however, a main effect of time on FSS score \[*F*(2,176) = 4.6, *p* = 0.011; $\eta_{p}^{2}$ = 0.050\], reflecting an overall reduction in fatigue between baseline and T1 (MD = 3.06, 95% CI: 0.386 -- 5.73, *SE* = 1.1, *p* = 0.019). In the ITT analysis of illness perception there was no longer a time by group interaction. There was, however, a time by group interaction with respect to PSS score reflecting a reduction in perceived stress symptoms relative to baseline in the BAM group both at T1 (MD = 5.49, 95% CI: 2.91 -- 8.07, *SE* = 1.06, *p* \< 0.001) and at T2 (MD = 4.18, 95% CI: 1.44 -- 6.92, SE = 1.12, *p* = 0.001).

Caregivers
----------

Nineteen caregivers agreed to participate in the same intervention group as the patient for whom they cared (BAM *n* = 9; PEI: *n* = 10). Half the participating caregivers (50%) were the mothers of MS patients (see Supplementary Table [2](#SM1){ref-type="supplementary-material"} for further details). One caregiver dropped out after the baseline assessment and another dropped out during the intervention phase. Due to the low number of caregivers that agreed to participate we were unable to evaluate the effects of the interventions on this population.

Discussion
==========

To the best of our knowledge, this is the first RCT to evaluate the effectiveness of a group-based MBI in MS patients with depressive symptoms by comparing it with a control intervention. In MS depression is one of the main determinants of patients' quality of life. It can increase fatigue and further compromise cognitive function and may also have a negative impact on relationships and reduce adherence to medication ([@B20]). For these reasons the Goldman Consensus Conference ([@B25]) and the American Academy of Neurology ([@B38]) have highlighted the importance of diagnosing and treating depression in people with MS.

Mindfulness-based interventions are a relatively brief and cost-effective psychological treatment that have been shown to reduce depressive symptoms and improve quality of life in patients with several chronic diseases ([@B29]; [@B17]; [@B64]; [@B28]). Recent systematic reviews concluded that MBIs could also help patients with MS, by reducing the mental (such as anxiety and depression) and physical (i.e., fatigue) symptoms and improving the patients' quality of life ([@B58]; [@B35]; [@B51]). However, none of these studies compared MBIs with an active control, which means that there are question marks over the specificity of the efficacy of MBIs.

When only patients who completed the interventions are considered, our RCT data indicate that the BAM intervention was more effective in reducing symptoms of depression (as measured by the BDI-II) than the PEI. Although both groups showed improvements in BDI-II score after the intervention and at the follow-up assessment, the BAM had lower BDI-II scores; this was a medium-sized effect. This finding extends previous research showing that in MS patients MBIs are effective when compared with standard care ([@B37]; [@B26]; [@B61]), by showing that a MBI was more effective than a psycho-educational intervention in reducing symptoms of depression. In the ITT analysis only the main effect of time remained statistically significant, weakening the evidence for the superior efficacy of the BAM intervention relative to the PEI. However, given that depressive symptoms can remit or reduce spontaneously ([@B48]), it is possible that this occurred in the patients who dropped out, reducing the difference between the two interventions and masking the superior efficacy of the BAM that was found in the PP analysis. It should be noted that in both the PP and ITT analyses, the BAM group's mean BDI-II score was below the threshold after the intervention, indicating the BAM intervention had a clinically meaningful impact on depressive symptoms.

The BAM-induced reduction in depressive symptoms as assessed by the BDI-II, which is a self-report measure, was replicated in the results from the semi-structured clinical interview (M.I.N.I.-Plus). Previous studies have relied on self-report outcome measures ([@B35]; [@B58]) and no previous studies have evaluated psychosocial functioning before and after an intervention using objective measures. The M.I.N.I.-Plus data confirmed that in the BAM group there was a reduction in the number of patients currently experiencing a major depressive episode or adjustment disorders after the intervention. The M.I.N.I.-Plus also showed a reduction in the number of patients in the BAM group who met the criteria for an anxiety disorder (generalized anxiety disorder, panic disorders or specific phobia). At the baseline assessment both groups reported mild to moderate levels of anxiety, in addition to high perceived stress.

The BAM intervention was no more effective than the PEI in reducing anxiety symptoms and perceived stress, according to the self-report data (BAI and PSS). Both treatments reduced symptoms and the effects were maintained at the follow-up assessment, suggesting that they were similarly effective in producing long-term improvements in these domains.

A recent review indicated that relative to no treatment or control treatments such as standard care or walking in the garden, MBIs have a positive impact on fatigue in neurological conditions such as stroke, traumatic brain injury and MS ([@B63]). In our study the BAM and PEI interventions were not effective (PP analysis) or only similarly effective (ITT analysis) in reducing fatigue. Further research into this area is needed.

After receiving a diagnosis of illness, individuals develop an organized pattern of cognitive and emotional representations of their own illness, which can be referred to as an illness perception ([@B45]). These beliefs can influence coping behavior ([@B34]), with negative illness perceptions being associated with poorer recovery and increased healthcare use, even after controlling for objective illness severity ([@B34]; [@B45]). Our PEI was not effective in modifying MS patients' illness perception, whereas patients in the BAM group reported less negative illness perceptions after the intervention, suggesting that the intervention had promoted a positive reorganization of their cognitive and emotional illness representations. A change in illness perceptions can help to reduce everyday disability and improve functioning and quality of life ([@B45]).

Mindfulness-based interventions have been shown to enhance quality of life in many different chronic conditions ([@B19]; [@B17]; [@B64]; [@B28]) and we confirmed this with respect to MS in our study. We found that the BAM intervention was effective in improving patients' overall quality of life, whereas the PEI was not. Furthermore, the improvement seen in the BAM group was maintained 6 months after the intervention had ended, suggesting that the BAM intervention induces long-term modifications in quality of life. In particular, the BAM intervention reduced problems with concentration, thinking and fatigue and improved scores on the general contentment subscale, which deals with satisfaction and acceptance of health-related quality of life. The only quality of life domain to show improvement in the PEI group was emotional wellbeing, and the BAM group showed a similar improvement.

Mindfulness-based interventions have been shown to have a low attrition rate and no side effects ([@B26]; [@B58]). In our study the two interventions had comparable attrition rates. Eight patients dropped out after group allocation (5 from the BAM group; 3 from the PEI group) and 11 patients dropped out during the treatment (3 from the BAM group; 7 from the PEI group). The majority of the latter category dropped out due for logistic or work-related reasons. Although the attrition rate was close to the acceptable threshold, which is 20% of randomized participants ([@B53]), the only baseline differences between completers and dropouts, were lower levels of anxiety and perceived stress in patients that dropped out of the PEI. Furthermore, only 4% of patients allocated to the BAM group refused to complete the post-treatment assessments, which allowed us to perform an ITT analysis.

Our study has some important limitations. One was the failure to recruit sufficient caregivers. Caregivers of patients with MS experience the stress and difficulties related to the management of a relative with a chronic disabling disease. Furthermore, patients' depression has a negative impact on the quality of life and mood of their caregivers ([@B24]). We were therefore interested in evaluating whether caregivers would benefit from the treatment. Unfortunately, we were unable to recruit and retain sufficient caregivers to warrant statistical analysis of their data. Another limitation is that owing to the characteristics of the intervention, which requires at least partially preserved mobility, we had to exclude severely disabled patients. Similarly, the high rate of refusal to participate in the study (45% of patients that fulfilled the criteria declined to participate) and the high dropout rate may be at least partially explained by logistic factors. The CReSM Unit is the regional reference center for MS, and thus patients travel to the center from a wide area. Mobility difficulties may have prevented or discouraged MS patients living further from the center from participating in the interventions. In view of the apparent efficacy of MBIs in MS patients it is therefore essential to develop new ways of delivering mindfulness-based protocols, such as eHealth programs, to render them more accessible.

In conclusion, this study is, to the best of our knowledge, the first RCT to compare the effectiveness of a MBI and psycho-educational intervention in MS patients. Other strengths of the study in addition to the use of an active control group are the focus on symptoms of depression and the use of a clinical interview to corroborate self-report data on psychological functioning. The results on completers strengthen the evidence that MBIs reduce depressive symptoms and enhance quality of life in patients with MS ([@B35]; [@B58]; [@B51]) as they demonstrate the effects of MBIs are specific to this type of intervention and are not the result of non-specific factors. Furthermore, the BAM intervention was shown to be effective in reducing negative representations of the illness, modulating cognitive and emotional aspects of illness perception and enhancing acceptance of the pathology. The BAM intervention also led to a reduction in anxiety symptoms and perceived stress, although it was no more effective in these respects than the PEI. This finding is not surprising, given that the BAM protocol was specifically tailored to manage depression. All the improvements observed immediately after the BAM intervention were maintained at the long-term follow-up assessment thus providing further supporting for the effectiveness of the BAM intervention in MS patients.
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